Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Anjarium Biosciences has raised $60.4M in total funding. The most recent round was Series A. The last funding was announced in September 2021.
Anjarium Biosciences's investors include Abingworth, Pfizer Venture Investments, Omega Funds, Gimv, Surveyor Capital.
Anjarium Biosciences is headquartered in Schlieren, Switzerland.
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Anjarium Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anjarium Biosciences — Funding & Investors." VCBacked, September 15, 2021, https://www.vcbacked.co/company/anjarium-biosciences. Accessed September 30, 2026.
VCBacked. (2021). Anjarium Biosciences — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/anjarium-biosciences
{{cite web |title=Anjarium Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/anjarium-biosciences |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated